Marshall Wace LLP boosted its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 162.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,122,296 shares of the company's stock after acquiring an additional 694,243 shares during the period. Marshall Wace LLP owned 0.17% of Genmab A/S worth $23,422,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of the business. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC boosted its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its position in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Price Performance
GMAB traded down $0.02 during trading on Friday, hitting $20.52. The company had a trading volume of 322,888 shares, compared to its average volume of 1,045,208. The company has a market cap of $13.58 billion, a PE ratio of 11.80, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The business has a 50-day moving average of $20.50 and a 200-day moving average of $21.08.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on GMAB shares. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Truist Financial decreased their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.17.
Read Our Latest Stock Report on Genmab A/S
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
